Indications
To control haemorrhage in: Epistaxis, haemoptysis, haematemesis,
melena, menorrhagia, post-surgical conditions.
Description
Tranexamic acid competitively inhibits activation of plasminogen
(via binding to the kringle domain), thereby reducing conversion
of plasminogen to plasmin (fibrinolysin), an enzyme that degrades
fibrin clots, fibrinogen, and other plasma proteins, including the
procoagulant factors V and VIII. Tranexamic acid also directly
inhibits plasmin activity, but higher doses are required than are
needed to reduce plasmin formation.
Dosage
As per the physician’s advice.
Note :This product
information is intended only for residents of the India.
Taj Pharmaceuticals Limited, medicines help to treat and prevent
a range of conditions—from the most common to the most
challenging—for people around the world.
Information for Health Care Professionals
*** Please consult local Prescribing
Information for any product before use. This website is an
international information resource for healthcare professionals
with an interest in disease management. This website is not
intended to replace the advice of a qualified healthcare
professional. Above brand is a trademark of the Taj group of
companies (Taj Pharmaceuticals Limited)
Quality
